IDHC vs. GENI, LLAI, DMTR, LLA, DXRX, AGL, YGEN, ABDX, GDR, and PRM
Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include GENinCode (GENI), LungLife AI (LLAI), Deepmatter Group (DMTR), LLA.L,0P0001T9GN,0 (LLA), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), genedrive (GDR), and Proteome Sciences (PRM). These companies are all part of the "diagnostics & research" industry.
Integrated Diagnostics vs.
Integrated Diagnostics (LON:IDHC) and GENinCode (LON:GENI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
43.0% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 47.6% of GENinCode shares are held by institutional investors. 34.0% of Integrated Diagnostics shares are held by company insiders. Comparatively, 39.8% of GENinCode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Integrated Diagnostics received 56 more outperform votes than GENinCode when rated by MarketBeat users.
Integrated Diagnostics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, GENinCode has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.
Integrated Diagnostics has a net margin of 17.21% compared to GENinCode's net margin of -228.70%. Integrated Diagnostics' return on equity of 23.03% beat GENinCode's return on equity.
Summary
Integrated Diagnostics beats GENinCode on 8 of the 12 factors compared between the two stocks.
Get Integrated Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integrated Diagnostics Competitors List
Related Companies and Tools
This page (LON:IDHC) was last updated on 1/22/2025 by MarketBeat.com Staff
Free IDHC Stock Alerts